The At its January 2023 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted two-_ Extensions recommended in oncology:
Darolutamide (Nubeqa, Bayer): In the future, the antiandrogen will also be indicated for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy. Until now, its use has been limited to castration-resistant prostate cancer.
Luspatercept (Reblozyl, Bristol Myers Squibb): The recombinant fusion protein is indicated in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent beta-thalassemia.Until now, its use has been limited to transfusion-dependent anaemia.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/moderne-therapien-der-h%25C3%25A4matologie-und-onkologie-2023a10002dq